207 related articles for article (PubMed ID: 22587521)
21. Current methodologies for detecting sensitization to HLA antigens.
Cecka JM
Curr Opin Organ Transplant; 2011 Aug; 16(4):398-403. PubMed ID: 21666477
[TBL] [Abstract][Full Text] [Related]
22. Successful transplantation across positive B-cell cross-match in deceased donor renal transplants.
Goh A; Oei E; Vathsala A
Transplant Proc; 2012 Jan; 44(1):193-9. PubMed ID: 22310613
[TBL] [Abstract][Full Text] [Related]
23. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification.
Gibney EM; Cagle LR; Freed B; Warnell SE; Chan L; Wiseman AC
Nephrol Dial Transplant; 2006 Sep; 21(9):2625-9. PubMed ID: 16644776
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
25. Increasing relevance of donor-specific antibodies in antibody-mediated rejection.
Zito A; Schena A; Grandaliano G; Gesualdo L; Schena FP
J Nephrol; 2013; 26(2):237-42. PubMed ID: 23475460
[TBL] [Abstract][Full Text] [Related]
26. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up.
Lachmann N; Terasaki PI; Schönemann C
Clin Transpl; 2006; ():171-99. PubMed ID: 18365377
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates.
Arnold ML; Dechant M; Doxiadis II; Spriewald BM
Tissue Antigens; 2008 Jul; 72(1):60-6. PubMed ID: 18588575
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
[TBL] [Abstract][Full Text] [Related]
29. Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy.
Eng HS; Bennett G; Chang SH; Dent H; McDonald SP; Bardy P; Coghlan P; Russ GR; Coates PT
Hum Immunol; 2011 May; 72(5):386-91. PubMed ID: 21320562
[TBL] [Abstract][Full Text] [Related]
30. Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums.
Gebel HM; Moussa O; Eckels DD; Bray RA
Hum Immunol; 2009 Aug; 70(8):610-7. PubMed ID: 19375473
[TBL] [Abstract][Full Text] [Related]
31. Allosensitization to HLA and MICA is an important measure of renal graft outcome.
Panigrahi A; Siddiqui JA; Rai A; Margoob A; Khaira A; Bhowmik D; Tiwari SC; Guleria S; Mehra NK
Clin Transpl; 2007; ():211-7. PubMed ID: 18637472
[TBL] [Abstract][Full Text] [Related]
32. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation.
Hourmant M; Cesbron-Gautier A; Terasaki PI; Mizutani K; Moreau A; Meurette A; Dantal J; Giral M; Blancho G; Cantarovich D; Karam G; Follea G; Soulillou JP; Bignon JD
J Am Soc Nephrol; 2005 Sep; 16(9):2804-12. PubMed ID: 16014742
[TBL] [Abstract][Full Text] [Related]
33. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
[TBL] [Abstract][Full Text] [Related]
34. Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation.
Cox ST; Stephens HA; Fernando R; Karasu A; Harber M; Howie AJ; Powis S; Zou Y; Stastny P; Madrigal JA; Little AM
Hum Immunol; 2011 Oct; 72(10):827-34. PubMed ID: 21664940
[TBL] [Abstract][Full Text] [Related]
35. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
36. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?
Gupta A; Iveson V; Varagunam M; Bodger S; Sinnott P; Thuraisingham RC
Transplantation; 2008 Apr; 85(8):1200-4. PubMed ID: 18431242
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic flow cytometric crossmatch in renal transplantation: a single assay to simultaneously detect antibody binding and cytotoxicity.
Thammanichanond D; Athimang W; Paisooksantivatana K; Mongkolsuk T; Ingsathit A; Worawichawong S; Kitpoka P; Jirasiritham S; Kantachuvesiri S
Transplant Proc; 2012 Jan; 44(1):62-5. PubMed ID: 22310580
[TBL] [Abstract][Full Text] [Related]
38. [Anti-HLA antibody detection and rejection in kidney transplantation: impact of the new technologies].
Georgescu D; Ferrari-Lacraz S; Villard J
Rev Med Suisse; 2007 Apr; 3(108):1064-9. PubMed ID: 17552259
[TBL] [Abstract][Full Text] [Related]
39. Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe?
Ferrari-Lacraz S; Tiercy JM; Villard J
Tissue Antigens; 2012 May; 79(5):315-25. PubMed ID: 22489941
[TBL] [Abstract][Full Text] [Related]
40. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT.
Yoshihara S; Maruya E; Taniguchi K; Kaida K; Kato R; Inoue T; Fujioka T; Tamaki H; Ikegame K; Okada M; Soma T; Hayashi K; Fujii N; Onuma T; Kusunoki Y; Saji H; Ogawa H
Bone Marrow Transplant; 2012 Apr; 47(4):508-15. PubMed ID: 21691261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
